Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other Non-Current Liabilities: 2022-2024

Historic Other Non-Current Liabilities for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $91.7 million.

  • Axsome Therapeutics' Other Non-Current Liabilities rose 8.30% to $89.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.9 million, marking a year-over-year increase of 8.30%. This contributed to the annual value of $91.7 million for FY2024, which is 25.08% up from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Other Non-Current Liabilities is $91.7 million, which was up 25.08% from $73.3 million recorded in FY2023.
  • Axsome Therapeutics' Other Non-Current Liabilities' 5-year high stood at $91.7 million during FY2024, with a 5-year trough of $31.1 million in FY2022.
  • In the last 3 years, Axsome Therapeutics' Other Non-Current Liabilities had a median value of $73.3 million in 2023 and averaged $65.4 million.
  • Data for Axsome Therapeutics' Other Non-Current Liabilities shows a peak YoY spiked of 135.69% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Other Non-Current Liabilities (Yearly) stood at $31.1 million in 2022, then surged by 135.69% to $73.3 million in 2023, then increased by 25.08% to $91.7 million in 2024.